Find any stock by ticker or company name
NGM – Real Time Price. Currency in USD
100.79
+0.12 (0.11%)
Market open: Aug 12, 2026, 12:14 PM EDT
100.68
0.00 (0.00%)
Previous after-hours: Aug 11, 2026, 7:34 PM EDT
Lantheus Holdings, Inc. develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in diagnosis and treatment of heart, cancer, and other diseases worldwide. The company offers DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer. It also provides Automated Bone Scan Index that calculates the disease burden of prostate cancer by detecting and classifying bone scan tracer uptakes as metastatic or benign lesions using an artificial neural network; RELISTOR for opioid-induced constipation; and aPROMISE, an artificial intelligence medical device software; PYLARIFY AI, an medical device software to perform quantitative assessment of PSMA PET/CT images in prostate cancer; and flurpiridaz used to assess blood flow to the heart. In addition, it develops PNT2002, a radiopharmaceutical therapy to treat mCRPC; PNT2003, an SSTR therapy to patients with SSTR-positive neuroendocrine tumors; MK-6240, a F 18-labeled PET imaging agent for Tau tangles in Alzheimer’s disease; LNTH-2401, a novel radiodiagnostic targeting the gastrin-releasing peptide receptor; LNTH-2402; LNTH-2403; LNTH-2404; LNTH-250; LNTH-2515; and LNTH-1363S, an fibroblast activation protein, alpha, copper-64 labeled PET imaging agent. It has collaboration agreements with GE Healthcare; Curium Pharma; POINT; Regeneron; and Ratio Therapeutics LLC. The company was founded in 1956 and is based in Bedford, Massachusetts.
| Name | Position |
|---|---|
| Dr. Ludger Dinkelborg Ph.D. | Head of Research & Development |
| Mr. Daniel M. Niedzwiecki | Chief Administrative Officer, General Counsel & Corporate Secretary |
| Mr. Mark Richard Kinarney | Vice President of Investor Relations |
| Mr. Neil Holland | VP of Business Insights & Operations |
| Mr. Robert J. Marshall Jr., CFA | CFO & Treasurer |
| Ms. Amanda M. Morgan | Chief Commercial Officer |
| Date | Type | Document |
|---|---|---|
| 2026-08-06 | 10-Q | lnth-20260630.htm |
| 2026-08-04 | DEFA14A | d112214ddefa14a.htm |
| 2026-08-03 | 8-K | d148563d8k.htm |
| 2026-05-29 | SD | d111325dsd.htm |
| 2026-05-07 | 8-K | lnth-20260507.htm |
| 2026-05-07 | 10-Q | lnth-20260331.htm |
| 2026-05-01 | 8-K | d16067d8k.htm |
| 2026-03-20 | DEF 14A | d61755ddef14a.htm |
| 2026-03-10 | PRE 14A | d61755dpre14a.htm |
| 2026-02-26 | 8-K | lnth-20260226.htm |
| Ms. Kimberly Brown | Chief Accounting Officer |
| Ms. Lee Anne Howe | Chief Information Officer |
| Ms. Linda S. Lennox | VP of Corporate Communications & Chief of Staff |
| Ms. Mary Anne Heino | CEO & Executive Chairperson |